Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Ezio Bonvini et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140